Proteome identifies prostate cancer biomarker

By Lisa Kerner

Charlotte, N.C., Sept. 6 - Proteome Systems is developing a semen-based prostate cancer test to improve the accuracy of the prostate-specific antigen test and has identified a prostate cancer biomarker associated with Human Carcinoma-Antigen, according to a company news release.

Human Carcinoma-Antigen is over-expressed in prostate cancer tissue but is absent or minimally present in normal or benign, enlarged prostate tissue. Correlation of the antigen with prostate cancer required the identification of a prostate-specific protein carrying the cancer-specific Human Carcinoma-Antigen marker, the Boston-based biotechnology company said.

Human Carcinoma-Antigen is licensed to Proteome's partner Egenix Inc., a New York-based biotechnology company.

Proteome said it expects its discovery to lead to more accurate, less invasive and timely testing of men for prostate cancer, the second most common cancer in men.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.